Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4447351
Max Phase: Preclinical
Molecular Formula: C52H77N10O23P
Molecular Weight: 1241.21
Molecule Type: Unknown
Associated Items:
ID: ALA4447351
Max Phase: Preclinical
Molecular Formula: C52H77N10O23P
Molecular Weight: 1241.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1cc(=O)oc2cc(OP(=O)(O)O)ccc12)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C)C(C)C
Standard InChI: InChI=1S/C52H77N10O23P/c1-11-24(8)42(61-52(80)43(25(9)63)62-48(76)34(20-38(69)70)56-46(74)33(19-37(67)68)54-26(10)64)51(79)58-32(15-27-16-39(71)84-35-17-28(12-13-29(27)35)85-86(81,82)83)47(75)59-41(23(6)7)50(78)60-40(22(4)5)49(77)57-31(14-21(2)3)45(73)55-30(44(53)72)18-36(65)66/h12-13,16-17,21-25,30-34,40-43,63H,11,14-15,18-20H2,1-10H3,(H2,53,72)(H,54,64)(H,55,73)(H,56,74)(H,57,77)(H,58,79)(H,59,75)(H,60,78)(H,61,80)(H,62,76)(H,65,66)(H,67,68)(H,69,70)(H2,81,82,83)/t24-,25+,30-,31-,32-,33-,34-,40-,41-,42-,43-/m0/s1
Standard InChI Key: IDSVIHXHBATOEG-BSJFHTPMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1241.21 | Molecular Weight (Monoisotopic): 1240.4901 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ma ES, Barrios AM.. (2019) Rational design of a SHP-2 targeted, fluorogenic peptide substrate., 29 (17): [PMID:31351693] [10.1016/j.bmcl.2019.07.034] |
Source(1):